We are live on ! Find out more
DA

DCF Advisers Portfolio holdings

AUM $375M
1-Year Est. Return 72.65%
This Fund
S&P 500
This Quarter Est. Return
+9.77%
1 Year Est. Return
+72.65%
3 Year Est. Return
+156.29%
5 Year Est. Return
+218.72%
10 Year Est. Return
–
AUM
$203M
AUM Growth
+$18.8M
Cap. Flow
+$773K
Cap. Flow %
0.38%
Top 10 Hldgs %
50.6%
Holding
95
New
11
Increased
22
Reduced
17
Closed
12

Top Buys

Rank Stock Value
1
BIDU icon
Baidu
BIDU
+$2.05M
2
AMGN icon
Amgen
AMGN
+$966K
3
TDOC icon
Teladoc Health
TDOC
+$933K
4
GDX icon
VanEck Gold Miners ETF
GDX
+$739K
5
PRTA icon
Prothena Corp
PRTA
+$684K

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.52M
2
XNCR icon
Xencor
XNCR
+$608K
3
IMGN
Immunogen Inc
IMGN
+$415K
4
ORCL icon
Oracle
ORCL
+$372K
5
BUR icon
Burford Capital
BUR
+$263K

Sector Composition

Rank Sector Weight
1 Healthcare 29.96%
2 Technology 19.82%
3 Communication Services 7.67%
4 Consumer Discretionary 3.77%
5 Financials 3.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
YETI icon
76
CALL
Yeti Holdings
YETI
$3.71B
$96.4K 0.05%
+2,500
New +$106K
TBHC
77
DELISTED
The Brand House Collective
TBHC
$61.3K 0.03%
25,415
– –
OVID icon
78
Ovid Therapeutics
OVID
$414M
$60.2K 0.03%
19,730
+1,000
+5% +$3.35K
AMRN
79
Amarin Corp
AMRN
$299M
$11.8K 0.01%
665
– –
ESPR
80
CALL
DELISTED
Esperion Therapeutics
ESPR
$9.38K ﹤0.01%
+3,500
New +$8.51K
ALNY icon
81
Alnylam Pharmaceuticals
ALNY
$27.5B
– –
-1,300
Closed -$249K
BABA icon
82
CALL
Alibaba
BABA
$293B
– –
-1,200
Closed -$93K
BABA icon
83
PUT
Alibaba
BABA
$293B
– –
-15,000
Closed -$1.16M
FXI icon
84
CALL
iShares China Large-Cap ETF
FXI
$4.37B
– –
-46,500
Closed -$1.12M
GDX icon
85
CALL
VanEck Gold Miners ETF
GDX
$22.7B
– –
-12,500
Closed -$388K
GLD icon
86
CALL
SPDR Gold Trust
GLD
$131B
– –
-6,500
Closed -$1.24M
INCY icon
87
CALL
Incyte
INCY
$24.2B
– –
-1,000
Closed -$62.8K
RBLX icon
88
Roblox
RBLX
$25.4B
– –
-5,000
Closed -$229K
TDOC icon
89
CALL
Teladoc Health
TDOC
$1.22B
– –
-15,000
Closed -$323K
UNG icon
90
United States Natural Gas Fund
UNG
$456M
– –
-2,875
Closed -$58.3K
ARQ icon
91
CALL
Arq
ARQ
$84.6M
– –
-4,000
Closed -$11.9K
IMGN
92
DELISTED
Immunogen Inc
IMGN
– –
-14,000
Closed -$415K
1 2 3
4

Similar funds

JIC
JRM Investment Counsel Omaha, Nebraska $375M AUM 13.43% 1-Year Est. Return
CIM
CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return
AIM
Access Investment Management Atlanta, Georgia $376M AUM 17.2% 1-Year Est. Return
MWM
McMill Wealth Management Norfolk, Nebraska $376M AUM 14.46% 1-Year Est. Return
RCP
RIT Capital Partners London, United Kingdom $374M AUM 25.18% 1-Year Est. Return
HPM
Helix Partners Management New York $374M AUM 136.73% 1-Year Est. Return
CAG
Compass Advisory Group Melville, New York $374M AUM 14.59% 1-Year Est. Return
LWMNY
Landmark Wealth Management (New York) Melville, New York $373M AUM 12.01% 1-Year Est. Return

DCF Advisers's Q1 2024 Portfolio in Review

As of Q1 2024, DCF Advisers held 95 positions worth $203M, up 10% from $184M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

DCF Advisers's Q1 2024 filing shows 11 new, 22 increased, 17 reduced and 12 closed positions. Its largest new stake was Baidu: 19,250 shares worth $2.03M. The largest sale was Regeneron Pharmaceuticals, an estimated $1.52M.

By sector, the portfolio is most concentrated in Healthcare at 30% of assets, down from 32% a quarter earlier, followed by Technology and Communication Services.

  • DCF Advisers's largest Q1 2024 buy was Baidu: 19,250 shares worth $2.03M.
  • DCF Advisers added most to Amgen in Q1 2024, an estimated $966K increase.
  • DCF Advisers's biggest Q1 2024 reduction was Regeneron Pharmaceuticals, cutting an estimated $1.52M.
  • DCF Advisers fully exited Immunogen Inc in Q1 2024, selling an estimated $415K.
  • DCF Advisers's ten largest holdings make up 51% of its $203M portfolio in Q1 2024.
  • DCF Advisers opened 11 new positions and closed 12 in Q1 2024.
  • DCF Advisers's portfolio value rose 10% quarter-over-quarter to $203M.

Based on DCF Advisers's 13F filing for Q1 2024, filed 15 May 2024.